Canada: Mayo On The Side?

The Canadian Patent Office Issues New Examination Guidelines for Medical Diagnostic Methods.

On June 29, 2015, the Canadian Intellectual Property Office (CIPO) issued a long-awaited Practice Notice PN 2015-02 ("Notice") on the subject of medical diagnostic methods.

The examination of Canadian patent applications with claims pertaining to diagnostics has been on hold pursuant to the November 2011 decision of the Federal Court of Appeal in respect of the Amazon 1-Click application.1 In response to routine status checks, CIPO returned a standardized form letter indicating that it considered this decision to be relevant to medical diagnostics, but that examination guidelines had not yet been established. Consequently, examination of such applications was deferred.

Practice Notice PN2015-02 provides these guidelines to CIPO examiners, and should mean that the three- and-a-half-year backlog of diagnostic-related applications awaiting an Office Action, or a Notice of Allowance, will now begin to clear.

The Notice indicates that examiners should apply the "problem and solution" approach established in a previous Practice Notice (PN 2013-02) to construe claims and identify their essential elements. Under this framework, once the underlying technical problem is discerned, the examiner may ignore, as non-essential, any claim feature that is considered to be extraneous to the solution.

Two categories of technical problems are described for diagnostic methods:

  • "Data acquisition" problems are said to be those solved, e.g., by disclosure of a new analyte ("non-common general knowledge" analyte2 is the term used), or by overcoming some technical problem related in the identification, detection, or measurement of an analyte. The Notice states that if an application provides a significant amount of technical detail on how the analyte is measured, this provides a clue that the invention solves a data acquisition problem.
  • "Data analysis" problems are said to be those solved by recognizing the significance of data, such as in the case of a new correlation. The Notice says that one clue that an invention solves a data analysis problem will be a relative lack of technical detail about data acquisition, or an indication that any known methods may be used. In this last point, the reader may discern parallels to the "conventional post-solution steps" element of the analysis applied by the U.S. Supreme  Court in Mayo3 and Alice4.

The Notice states that if a claim includes a physical step of data acquisition that is determined to be essential, then it is likely to be statutory. On the other hand, claims having essential elements limited to the mental analysis and/or intellectual significance of data (so-called "disembodied" steps) are likely not statutory. The Notice indicates that the latter would "generally apply to situations where the identified solution is only provided by an element or set of elements associated with the analysis or significance of the acquired data (e.g., the correlation)."


Under the framework, identification of the technical solution informs the entire analysis of essentiality, and so the way in which the underlying technical problem is understood by an examiner is very important. On the positive side, the new Notice grants examiners significant discretion to make decisions about subject matter eligibility, and flexibility to frame and reframe the problem and solution throughout examination, if necessary.

However, the Notice also leaves many questions unanswered. What qualifies as a "non-common general knowledge analyte", for instance? Is it only an absolutely new molecule, or can it be a new variant in a known molecule, a known molecule or variant that has never before been associated with disease, or a novel selection of known biomarkers in a particularly advantageous panel? Here, the Notice provides no specific insight.

In the absence of a Mayo-like test for subject matter eligibility in Canada, a finding that data acquisition is somehow "inessential" to a diagnostic involving a new correlation seems illogical. CIPO may be attempting to draw parallels here to the allegedly dispensable nature of computers to some computer- implemented business methods (e.g. when steps can purportedly be carried out mentally). There is a clear distinction here: it would be quite impossible to carry out a diagnostic method without a data acquisition step. Therefore, it may be argued that a claim is statutory simply by referring to the Practice Notice's own provision that an essential physical step of data acquisition is sufficient.

Of course, there are also many situations in which data acquisition problems and data analysis problems are inextricably tied together, making the assignment of claims to one of two distinct categories both contrived and arbitrary.

At the drafting stage, the new guidelines indicate that it may be important to highlight any data acquisition problems overcome by the inventors in the course of their work. Post-drafting, those considering national filings in Canada can take heart that the door is not shut to diagnostic methods by the Notice, and that the law may be clarified before their applications are examined. Those with pending applications in Canada may find comfort in the flexibility of Canadian practice with regard to claim amendments, and the lack of excess claims fees. The Notice is squarely limited to the assessment of "method" claims, and there may be opportunities to assert related claim formats in response to an objection.

For the three-and-a-half years that it took to publish, the Notice seems to maintain and codify the status quo; the practical impact will probably be similar to objections some applicants saw prior to CIPO's decision to defer the examination of these applications. While the Notice builds on other Practice Notices released in the wake of Amazon, it is devoidof specific case law citations itself. This is curious, given that Canadian courts have on more than one occasion cautioned against the refusal of patents based on policy considerations.5,6


1. Canada (Attorney General) v Inc, 2011 FCA 328 [Amazon].

2. The Notice indicates that the term "analyte" is used broadly to mean a chemical substance or biomarker that is the subject of analysis.

3. Mayo Collaborative Services v Prometheus Laboratories Inc, 80 USLW 4225 (US 2012) [Mayo].

4. Alice Corp v CLS Bank International, 82 USLW 4508 (US 2014) [Alice ].

5. Harvard College v Canada (Commissioner of Patents), 2002 SCC 76 at para 144, cited with approval in Amazon supra note 1 at para 31.

6. Abbott Laboratories (Bermuda) Ltd v Abbvie Biotechnology Ltd, 2014 FC 1251 at para125.

About BLG

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Smart & Biggar/Fetherstonhaugh
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Smart & Biggar/Fetherstonhaugh
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions